Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanjietongqiao prescription is a Traditional Chinese Medicine (TCM) formula developed by the Shandong University of Traditional Chinese Medicine for the treatment of adenoid hypertrophy in children. The prescription is designed to address the core symptoms of the condition, such as nasal obstruction, snoring, and mouth breathing, by potentially reducing the size of the adenoids. In clinical research (e.g., ChiCTR2100052064), it has been evaluated in parallel-group interventional studies comparing its efficacy and safety against standard Western pharmacological treatments, including the leukotriene receptor antagonist montelukast and the corticosteroid mometasone furoate nasal spray.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sanjietongqiao prescription.